ClinicalTrials.gg
CompletedNCT04123366Updated Jun 23, 2026

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

A Phase 2 interventional study of Olaparib and Pembrolizumab in Solid Tumors, sponsored by Merck Sharp & Dohme LLC. Completed at 135 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
333
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a - or cytologically-confirmed advanced ( and/or unresectable) solid tumor (except breast or ovarian cancers whose tumor has a germline or somatic BRCA mutation) that is not eligible for curative treatment and for which standard of care therapy has failed. Participants must have progressed on or be intolerant to standard of care therapies that are known to provide clinical benefit. There is no limit on the number of prior treatment regimens.
  • Has either centrally-confirmed known or suspected deleterious mutations in ≥1 of the specified 15 genes involved in HRR or centrally-confirmed HRD based on the Lynparza HRR-HRD assay.
  • Has per 1.1 as assessed by the local site investigator/radiology and confirmed in real time by blinded independent central review (BICR). BICR must confirm the presence of radiologically measurable disease per RECIST 1.1 for the participant to be eligible for the study.
  • Has a of ≥3 months.
  • Must have had CR or PR while on the last treatment with prior cisplatin or carboplatin, or if received only oxaliplatin had CR, PR, or stable disease (SD) while on the last treatment with prior oxaliplatin (either as monotherapy or in combination) for advanced (metastatic and/or unresectable) solid tumor. Participant must also not have been to prior platinum-containing therapy.
  • Has an (ECOG) performance status of either 0 or 1, as assessed within 3 days of study treatment initiation.
  • Male participants must agree to use during the treatment period and for ≥90 days (3 months) after the last dose of olaparib and refrain from donating sperm during this period.
  • Female participants must not be pregnant or breastfeeding, and ≥1 of the following conditions applies: Is not a woman of (WOCBP) OR Is a WOCBP who agrees to use contraception during the treatment period and for ≥120 days (3 months) after the last dose of pembrolizumab and 180 days (6 months) after the last dose of olaparib, has a highly sensitive pregnancy test within 24 hours for urine or within 72 hours for serum before the first dose of study intervention, and abstains from breastfeeding during the study intervention period and for at least 120 days after the last dose of the study intervention.
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Has a known additional that is progressing or has required active treatment in the last 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, ductal carcinoma in situ, or cervical carcinoma in situ that has undergone potentially curative therapy are not excluded.
  • Has a history of non-infectious pneumonitis/interstitial lung disease that required treatment with or currently has pneumonitis/interstitial lung disease.
  • Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
  • Has known central nervous system (CNS) and/or carcinomatous meningitis.
  • Has an active infection requiring systemic therapy.
  • Has active tuberculosis (Bacillus tuberculosis [TB]).
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (dosing >10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of study treatment.
  • Has an active disease that has required systemic treatment in the past 2 years.
  • Has received colony-stimulating factors (e.g. granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF] or recombinant erythropoietin) within 28 days prior to the first dose of study treatment.
  • Has a known history of (HIV) infection.
  • Has known active or .
  • Is unable to swallow orally administered medication or has a gastrointestinal (GI) disorder affecting absorption (e.g. gastrectomy, partial bowel obstruction, malabsorption).
  • Has received prior therapy with an anti-programmed death-1 (), anti-programmed death-ligand 1 (anti-PD-L1), or anti-programmed death-ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX 40 [Tumor necrosis factor receptor superfamily, member 4 (TNFRSF4)], CD137 [tumor necrosis factor receptor superfamily member 9 (TNFRSF9)]).
  • Has received prior therapy with olaparib or with any other polyadenosine 5' diphosphoribose (poly[ADP ribose]) polymerization (PARP) inhibitor.
  • Has received prior systemic anti-cancer therapy including agents within 4 weeks prior to administration of study treatment.
  • Must have recovered from all adverse events (AEs) due to previous therapies, excluding alopecia, to ≤Grade 1 or Baseline.
  • Has a known to the study treatments and/or any of their .
  • Is currently receiving either strong inhibitors of cytochrome P450 (CYP)3A4 (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate inhibitors of (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil) that cannot be discontinued for the duration of the study. The required prior to starting olaparib is 2 weeks.
  • Is currently receiving either strong inducers of CYP3A4 (phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate inducers of CYP3A4 (e.g. bosentan, efavirenz, modafinil) that cannot be discontinued for the duration of the study. The required washout period prior to starting olaparib is 5 weeks for phenobarbital and 3 weeks for other agents.
  • Has received previous allogenic bone-marrow transplant or double umbilical cord transplantation (dUCBT).
  • Has received a whole blood transfusion in the last 120 days prior to entry to the study.
  • Has received prior radiotherapy within 2 weeks of start of study treatment.
  • Is currently enrolled in and receiving study therapy, was enrolled in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks (28 days) of the first dose of study treatment.
  • The presence of uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g. unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, interval by Fredericia [QTcF] prolongation >500 msec, electrolyte disturbances), or participant has congenital long QT syndrome.
  • Has either had major surgery within 2 weeks of starting study treatment or has not recovered from any effects of any major surgery.
  • Has received a within 30 days prior to the first dose of study treatment.
  • Has had an allogenic tissue/solid tumor organ transplant.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
333 participants (actual)

Study arms

  • Experimental
    Olaparib+Pembrolizumab

    Participants receive olaparib 300 mg via oral tablet 2 times each day PLUS pembrolizumab 200 mg via intravenous infusion on Day 1 of each 21-day cycle. Participants may receive olaparib+pembrolizumab for up to approximately 2 years.

    Drug: Olaparib · Biological: Pembrolizumab

Interventions

  • Oral tablet

    Also known as: MK-7339, LYNPARZA®

  • BiologicalPembrolizumab

    Intravenous infusion

    Also known as: MK-3475, KEYTRUDA®

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or Prostate Cancer Working Group (PCWG)-modified RECIST 1.1 in Biomarker Subgroups

    ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The ORR for all participants will be presented by biomarker subgroup.

    Time frame: Up to ~3 years

Secondary outcomes

  1. Duration of Response (DOR) as Assessed by RECIST 1.1 or PCWG-modified RECIST 1.1 in Biomarker Subgroups

    For participants who demonstrate a confirmed complete response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death. The DOR for all participants who experience a CR or PR will be presented by biomarker subgroup.

    Time frame: Up to ~3 years

  2. Progression-Free Survival (PFS) as Assessed by RECIST 1.1 or PCWG-modified RECIST 1.1 in Biomarker Subgroups

    PFS is defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more lesions is also considered PD. The PFS for all participants will be presented by biomarker subgroup.

    Time frame: Up to ~3 years

  3. Overall Survival (OS) in Biomarker Subgroups

    OS is the time from randomization to death due to any cause. The OS for all participants will be presented by biomarker subgroup.

    Time frame: Up to ~3 years

  4. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience at least one AE will be presented.

    Time frame: Up to ~3 years

  5. Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment will be presented.

    Time frame: Up to ~3 years

  6. Objective Response Rate (ORR) Based on Tumor Biomarker Status as Assessed by RECIST 1.1 or PCWG-modified RECIST 1.1 in Additional Biomarker Subpopulations

    ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. ORR will be presented by biomarker subpopulation.

    Time frame: Up to ~3 years

  7. Duration of Response (DOR) Based on Tumor Biomarker Status as Assessed by RECIST 1.1 or PCWG-modified RECIST 1.1 in Additional Biomarker Subpopulations

    For participants who demonstrate a confirmed complete response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death. The DOR for all participants who experience a CR or PR will be presented by biomarker subpopulation.

    Time frame: Up to ~3 years

  8. Progression-Free Survival (PFS) Based on Tumor Biomarker Status as Assessed by RECIST 1.1 or PCWG-modified RECIST 1.1 in Additional Biomarker Subpopulations

    PFS is defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more lesions is also considered PD. PFS will be presented by biomarker subpopulation.

    Time frame: Up to ~3 years

  9. Overall Survival (OS) in Additional Biomarker Subpopulations

    OS is the time from randomization to death due to any cause. OS will be presented by biomarker subpopulation.

    Time frame: Up to ~3 years

  10. Number of Participants with Cancer Antigen-125 (CA-125) Level of ≥2 × Upper Limit of Normal (ULN) Among Participants with Ovarian Cancer

    The number of participants who have ovarian cancer and have a CA-125 level ≥2 × upper limit of normal (ULN) at 2 different assessments that are measured at least 1 week apart will be presented.

    Time frame: Up to ~3 years

  11. Number of Participants with Cancer Antigen-125 (CA-125) Level ≥2 × Nadir (Lowest) Value Among Participants with Ovarian Cancer Who Had Elevated CA-125 Levels ≥ULN at Baseline

    The number of participants who have ovarian cancer with an elevated CA-125 level ≥ ULN at Baseline and have a CA-125 level ≥2 × the nadir (lowest) value at 2 different assessments that are measured at least 1 week apart will be presented.

    Time frame: Up to ~3 years

  12. Number of Participants with a Change from Baseline in Prostate-Specific Antigen (PSA) Level of ≥50% Among Participants with Prostate Cancer

    A PSA response is defined as a reduction in the PSA level of ≥50% from Baseline measured at 2 different times at least 3 weeks apart. The number of participants who have prostate cancer and have a change from Baseline in PSA level ≥50% will be presented.

    Time frame: Up to ~3 years

07

Study locations

135 sites
  • The Kirklin Clinic ( Site 0086)
    Birmingham, Alabama 35233, United States
  • Banner MD Anderson Cancer Center ( Site 0049)
    Gilbert, Arizona 85234, United States
  • UC Davis Comprehensive Cancer Center ( Site 0039)
    Sacramento, California 95817, United States
  • San Francisco Oncology Associates ( Site 0085)
    San Francisco, California 94115, United States
  • University of California San Francisco ( Site 0015)
    San Francisco, California 94158, United States
  • Banner MD Anderson Cancer Center ( Site 0092)
    Greeley, Colorado 80631, United States
  • University of Florida ( Site 0078)
    Gainesville, Florida 32608, United States
  • Winship Cancer Institute of Emory University ( Site 0057)
    Atlanta, Georgia 30322, United States
  • Northeast Georgia Medical Center ( Site 0026)
    Gainesville, Georgia 30501, United States
  • Northwest Georgia Oncology Centers PC ( Site 0047)
    Marietta, Georgia 30060, United States
  • Norton Cancer Institute - St. Matthews ( Site 0024)
    Louisville, Kentucky 40207, United States
  • Atlantic Health System ( Site 0046)
    Summit, New Jersey 07901, United States
  • New York Cancer and Blood Specialists-Research Department ( Site 0080)
    Port Jefferson Station, New York 11776, United States
  • University Hospitals Cleveland Medical Center ( Site 0016)
    Cleveland, Ohio 44106, United States
  • The University of Oklahoma Health Sciences Center ( Site 0050)
    Oklahoma City, Oklahoma 73104, United States
  • Parkland Health & Hospital System ( Site 0091)
    Dallas, Texas 75235, United States
  • University of Texas, Southwestern Medical Center ( Site 0004)
    Dallas, Texas 75390, United States
  • University of Texas-MD Anderson Cancer Center ( Site 0087)
    Houston, Texas 77030, United States
  • Utah Cancer Specialists ( Site 0038)
    West Valley City, Utah 84119, United States
  • Inova Schar Cancer Institute ( Site 0008)
    Fairfax, Virginia 22031, United States
  • Northwest Medical Specialties, PLLC ( Site 0007)
    Tacoma, Washington 98405, United States
  • Fundacion CIDEA ( Site 2704)
    Ciudad de Buenos Aires, Buenos Aires F.D. C1121ABE, Argentina
  • Hospital Britanico de Buenos Aires ( Site 2705)
    Ciudad de Buenos Aires, Buenos Aires F.D. C1280AEB, Argentina
  • Centro Medico Dra De Salvo ( Site 2702)
    Buenos Aires, C1426ABP, Argentina
  • CEMIC ( Site 2701)
    Buenos Aires, C1431FWO, Argentina
  • Centro Oncologico Riojano Integral ( Site 2703)
    La Rioja, F5300COE, Argentina
  • Blacktown Hospital ( Site 2202)
    Blacktown, New South Wales 2148, Australia
  • Tasman Oncology Research Pty Ltd ( Site 2203)
    Southport, Queensland 4215, Australia
  • Monash Medical Centre ( Site 2205)
    Clayton, Victoria 3168, Australia
  • Linear Clinical Research Ltd ( Site 2206)
    Nedlands, Western Australia 6009, Australia
  • BC Cancer-Vancouver Center ( Site 0203)
    Vancouver, British Columbia V5Z 4E6, Canada
  • Moncton Hospital - Horizon Health Network ( Site 0206)
    Moncton, New Brunswick E1C 6Z8, Canada
  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0201)
    Montreal, Quebec H2X 1R9, Canada
  • Fundación Colombiana de Cancerología Clínica Vida ( Site 2902)
    Medellín, Antioquia 050030, Colombia
  • Clinica de la Costa S.A.S. ( Site 2900)
    Barranquilla, Atlántico 080020, Colombia
  • Fundacion Cardiovascular de Colombia ( Site 2907)
    Piedecuesta, Santander Department 68017, Colombia
  • Hemato Oncologos S.A. ( Site 2910)
    Cali, Valle del Cauca Department 76001, Colombia
  • Fundacion Valle del Lili ( Site 2909)
    Cali, Valle del Cauca Department 760032, Colombia
  • CHU Jean Minjoz ( Site 0606)
    Besançon, Doubs 25030, France
  • Institut du Cancer de Montpellier ( Site 0610)
    Montpellier, Herault 34298, France
  • Centre Henri Becquerel ( Site 0607)
    Rouen, Seine-Maritime 76038, France
  • Institut Gustave Roussy ( Site 0602)
    Villejuif, Val-de-Marne 94800, France
  • CHD Vendee ( Site 0604)
    La Roche-sur-Yon, Vendee 85925, France
  • Universitaetsklinik der Ludwig-Maximilians-Universitaet Muenchen ( Site 0906)
    Munich, Bavaria 81377, Germany
  • Universitaetsklinik Koeln ( Site 0903)
    Cologne, North Rhine-Westphalia 50937, Germany
  • Charite-Universitaetsmedizin Berlin-Campus Benjamin Franklin ( Site 0902)
    Berlin, 12203, Germany
  • Oncologika S.A. ( Site 3003)
    Guatemala City, 01010, Guatemala
  • Grupo Angeles SA ( Site 3004)
    Guatemala City, 01015, Guatemala
  • Sanatorio Nuestra Senora del Pilar ( Site 3006)
    Guatemala City, 01015, Guatemala
  • Medi-K Cayala ( Site 3005)
    Guatemala City, 01016, Guatemala
  • Centro Medico Integral De Cancerología (CEMIC) ( Site 3002)
    Quetzaltenango, 09002, Guatemala
  • Rambam Health Care Campus-Oncology Division ( Site 0801)
    Haifa, 3109601, Israel
  • Hadassah Ein Kerem Medical Center ( Site 0802)
    Jerusalem, 9112001, Israel
  • Meir Medical Center ( Site 0804)
    Kfar Saba, 4428164, Israel
  • Rabin Medical Center ( Site 0806)
    Petah Tikva, 4941492, Israel
  • Chaim Sheba Medical Center ( Site 0800)
    Ramat Gan, 5262000, Israel
  • Sourasky Medical Center ( Site 0805)
    Tel Aviv, 6423906, Israel
  • Azienda Ospedaliero Universitaria di Modena Policlinico ( Site 0703)
    Modena, Emilia-Romagna 41124, Italy
  • ASST Grande Ospedale Metropolitano Niguarda ( Site 0700)
    Milan, 20162, Italy
  • Istituto Nazionale Tumori Fondazione Pascale ( Site 0705)
    Naples, 80131, Italy
  • Azienda Ospedaliera Universitaria Senese ( Site 0704)
    Siena, 53100, Italy
  • Aichi Cancer Center Hospital ( Site 2504)
    Nagoya, Aichi-ken 464-8681, Japan
  • National Cancer Center Hospital East ( Site 2500)
    Kashiwa, Chiba 277-8577, Japan
  • Hokkaido University Hospital ( Site 2502)
    Sapporo, Hokkaido 060-8648, Japan
  • Kyushu University Hospital ( Site 2506)
    Fukuoka, 812-8582, Japan
  • Okayama University Hospital ( Site 2505)
    Okayama, 700-8558, Japan
  • National Cancer Center Hospital ( Site 2501)
    Tokyo, 104-0045, Japan
  • Japanese Foundation for Cancer Research ( Site 2503)
    Tokyo, 135-8550, Japan
  • Daugavpils Regional Hospital ( Site 2104)
    Daugavpils, 5417, Latvia
  • Liepaja Regional Hospital ( Site 2101)
    Liepāja, 3414, Latvia
  • Riga East Clinical University Hospital ( Site 2103)
    Riga, 1079, Latvia
  • P. Stradina Clinical University Hospital ( Site 2102)
    Riga, LV-1002, Latvia
  • Preparaciones Oncologicas ( Site 3102)
    León, Guanajuato 37178, Mexico
  • Unidad Biomedica Avanzada Monterrey S. A. ( Site 3108)
    Monterrey, Nuevo León 64460, Mexico
  • Centro Medico Zambrano Hellion ( Site 3105)
    San Pedro Garza García, Nuevo León 66278, Mexico
  • Hospital H+ Queretaro ( Site 3104)
    Querétaro City, Querétaro 76000, Mexico
  • Centro de Estudios de Investigacion Metabolicos y Cardiovasculares ( Site 3101)
    Madero, Tamaulipas 89440, Mexico
  • CRYPTEX Investigacion Clinica S.A. de C.V. ( Site 3103)
    Mexico City, 06100, Mexico
  • Clinica Integral Internacional de Oncologia S. de R.L. de C.V. ( Site 3107)
    Puebla City, 72530, Mexico
  • Hospital Nacional Carlos Alberto Seguin Escobedo ESSALUD ( Site 3206)
    Arequipa, Ariqipa 04001, Peru
  • Hospital Nacional Daniel Alcides Carrion ( Site 3207)
    Bellavista, Qallaw 07021, Peru
  • Hospital Nacional Adolfo Guevara Velasco ( Site 3205)
    Cuzco, Qusqu 08003, Peru
  • Oncosalud ( Site 3200)
    Lima, 15036, Peru
  • Instituto Nacional de Enfermedades Neoplasicas ( Site 3201)
    Lima, 15038, Peru
  • Hospital Nacional Arzobispo Loayza ( Site 3208)
    Lima, 15082, Peru
  • Clinica San Gabriel ( Site 3202)
    Lima, 15088, Peru
  • Hospital Nacional Cayetano Heredia ( Site 3203)
    Lima, 15102, Peru
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
    Warsaw, Masovian Voivodeship 02-781, Poland
  • Uniwersyteckie Centrum Kliniczne ( Site 1809)
    Gdansk, Pomeranian Voivodeship 80-214, Poland
  • Hematology and Oncology Institute ( Site 0504)
    Manati, 00674, Puerto Rico
  • Ad-Vance Medical Research LLC ( Site 0505)
    Ponce, 00717, Puerto Rico
  • Pan American Center for Oncology Trials LLC ( Site 0501)
    Rio Piedras, 00935, Puerto Rico
  • FDI Clinical Research ( Site 0500)
    San Juan, 00927, Puerto Rico
  • Spitalul Judetean de Urgenta Alba Iulia ( Site 1107)
    Alba Iulia, Alba 510007, Romania
  • Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 1101)
    Cluj-Napoca, Cluj 400015, Romania
  • Medisprof ( Site 1102)
    Cluj-Napoca, Cluj 400641, Romania
  • S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1103)
    Craiova, Dolj 200542, Romania
  • Policlinica Oncomed SRL ( Site 1104)
    Timișoara, Timiș County 300239, Romania
  • Universitas Annex National Hospital ( Site 1902)
    Bloemfontein, Free State 9301, South Africa
  • Wits Clinical Research ( Site 1906)
    Parktown-Johannesburg, Gauteng 2193, South Africa

Showing the first 100 of 135 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Cannon TL, Randall JN BA, Sokol ES, Alexander SM, Wadlow RC, Winer AA, Barnett DM, Rayes DL BS, Nimeiri HS, McGregor KA. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS. Cancer Treat Res Commun. 2022;32:100569. doi: 10.1016/j.ctarc.2022.100569. Epub 2022 Apr 30. PubMed 35567913 ↗

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Jun 2026, 78 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2019
First posted
Oct 10, 2019
StartActual
Nov 18, 2019
Primary completionActual
Jun 8, 2026
CompletionActual
Jun 8, 2026
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04123366
Responsible party
Sponsor
First posted
Oct 10, 2019
Start date
Nov 18, 2019
Primary completion
Jun 8, 2026
Completion
Jun 8, 2026
Last update
Jun 23, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Olaparib · Pembrolizumab

Start the discussion